美股A股
StockGist
Back
10-Q2026-05-13· deepseek-chat

ELDN · Eledon Pharmaceuticals, Inc.

0001193125-26-221702

SEC filing

Summary

Eledon's Q1 2026 net loss widened to $39.0M, driven by a non-cash increase in warrant liability fair value due to stock price appreciation.

Key takeaways

Full analysis

Non-Cash Warrant Revaluation Drove the Headline Loss

Operating Loss Reflects Strategic Manufacturing Investment

Cash Burn Accelerates on Working Capital Timing

Liquidity Position and Outlook